ArticleJournal of cancer treatment & diagnosis2025
Pharmacological Inhibition of cFLIP Targets Breast Cancer Stem Cells.
Article in Journal of cancer treatment & diagnosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Therapeutic targeting of tumour initiating, cancer stem cells (CSCs), offers the potential to improve long-term responses to cancer treatments. The apoptosis related protein Cellular FLICE-Like Inhibitory Protein (cFLIP) has previously been reported to protect breast cancer cells and breast CSCs from the cytotoxic effects of chemotherapy and apoptosis-inducing agents. We recently described the development of a small-molecule protein-protein inhibitor of cFLIP (OH14) that sensitizes refractory breast cancer cells to the death-receptor agonist Tumour Necrosis Factor Alpha Receptor Apoptosis Inducing Ligand (TRAIL). Here we investigated whether the pharmacological inhibition of cFLIP also targeted breast CSCs. Human breast cancer cell lines and primary-derived breast cancer samples were subjected to OH14 with or without TRAIL and assessed for bCSC viability by colony-formation and tumoursphere assay
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.